Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Preston Mason

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|August 9, 2006
Nitric oxide mechanisms in the pathogenesis of global riskR Preston Mason
Current Drug Targets. Cardiovascular & Haematological Disorders|March 1, 2006
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidenceR Preston Mason
Current Atherosclerosis Reports|January 15, 2019
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular DiseaseR Preston Mason
Vascular Health and Risk Management|July 29, 2011
Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomilR Preston Mason
Cerebrovascular Diseases (Basel, Switzerland)|May 13, 2003
Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific researchR Preston Mason
Atherosclerosis|November 6, 2002
Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidenceR Preston Mason
The American Journal of Medicine|December 17, 2005
A rationale for combination therapy in risk factor management: a mechanistic perspectiveR Preston Mason
Drugs|May 7, 2008
Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor managementR Preston Mason
Current Hypertension Reports|May 22, 2012
Pleiotropic effects of calcium channel blockersR Preston Mason
The American Journal of Cardiology|November 28, 2006
Molecular basis of differences among statins and a comparison with antioxidant vitaminsR Preston Mason
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Journal of Clinical Hypertension (Greenwich, Conn.)|August 9, 2006
Nitric oxide mechanisms in the pathogenesis of global riskR Preston Mason
Current Drug Targets. Cardiovascular & Haematological Disorders|March 1, 2006
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidenceR Preston Mason
Current Atherosclerosis Reports|January 15, 2019
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular DiseaseR Preston Mason
Vascular Health and Risk Management|July 29, 2011
Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomilR Preston Mason
Cerebrovascular Diseases (Basel, Switzerland)|May 13, 2003
Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific researchR Preston Mason
Atherosclerosis|November 6, 2002
Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidenceR Preston Mason
The American Journal of Medicine|December 17, 2005
A rationale for combination therapy in risk factor management: a mechanistic perspectiveR Preston Mason
Drugs|May 7, 2008
Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor managementR Preston Mason
Current Hypertension Reports|May 22, 2012
Pleiotropic effects of calcium channel blockersR Preston Mason
The American Journal of Cardiology|November 28, 2006
Molecular basis of differences among statins and a comparison with antioxidant vitaminsR Preston Mason
Pageof 10